Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of emicizumab during and after immune tolerance induction in congenital hemophilia A with FVIII inhibitors
jRCTs041200037Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of emicizumab and Factor VIII in hemophilia A, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Adverse events and Abnormal laboratory values. Started Nov 2020; status: active, not recruiting.
02
Drugs
emicizumabFactor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCTs041200037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200037.